BioXcel Therapeutics, Inc. (BTAI)
Oxford Ledge is still expanding full research coverage of BTAI. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
BioXcel Therapeutics uses AI to develop medicines in neuroscience and immuno-oncology, with an FDA-approved schizophrenia and bipolar disorder treatment and ongoing cancer research.
SEC filings
- 8-K Entry into material agreement; Financial statements and exhibits 2026-07-06
- 8-K Results of operations / financial condition; Financial statements and exhibits 2026-05-15
- 10-Q Quarterly financial report (unaudited) 2026-05-15
- 8-K 3.02; Financial statements and exhibits 2026-04-17
- 8-K Other material event 2026-04-01
Source: SEC EDGAR.
Annual results
5 years of annual figures for BTAI, as filed with the SEC. Figures are as reported and are not restated or adjusted.
| Fiscal year | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| 2025 | $642,000 | -$69.9M | -$5.73 |
| 2024 | $2.3M | -$59.6M | -$23.51 |
| 2023 | $1.4M | -$179.1M | -$98.33 |
| 2022 | $375,000 | -$165.8M | -$5.92 |
| 2021 | — | -$106.9M | -$4.05 |
Source: SEC EDGAR (XBRL company facts). Full statements and ratios in the terminal.
Insider activity
5 recent insider (SEC Form 4) filings on record for BTAI. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open BTAI in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.